Manila Times Business
Ractigen Therapeutics Announces ADA 2026 Late-Breaking Presentation Highlighting saRNA as a New Frontier in Obesity Control
Breakthrough preclinical data demonstrate that LiCO-saUcp1 effectively turns white fat into calorie-burning brown fat, driving massive fat loss while fully preserving lean muscle mass and preventing post-treatment weight rebound. NEW ORLEANS, June 6, 2026 /PRNewswire/ -- Ractigen Therapeutics, a pioneering clinical-stage biotechnology company developing innovative small activating RNA (saRNA) therapeutics, today announced that a late-breaking abstract on LiCO-saUcp1, its first-in-class saRNA can
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Ebola outbreak in Central Africa could reach 20,000 cases without strong public health measures
1h ago
Stocks slump as Big Tech sinks and a strong May jobs report boosts odds for higher interest rates
1h ago
Palace urges authorities to probe alleged June 12 attack plan
1h ago
ICC prepares high-tech case management platform for Duterte proceedings
2h ago